Lunit Oncology

Lunit develops state-of-the-art AI-powered medical image analysis software, led by a team of 300+ people, including 70+ researchers, 10+ MDs, and 6 oncologists/pathologists. Our highly skilled team consistently publishes in prestigious journals such as the Journal of Clinical Oncology, Clinical Cancer Research, JITC, NPJ, Precision Oncology, and more. Our AI-powered multimodal analysis unlocks advances in oncology research and clinical practice. Lunit SCOPE IO enables comprehensive tumor microenvironment assessment through quantitative immune phenotyping and beyond, facilitating faster and more accurate biomarker identification. Lunit SCOPE uIHC offers quantification and feature scoring IHC analysis across tissue types, for any suite of IHC markers. Lunit SCOPE GP predicts genotype modalities, offering insights into specific gene expression, mutations, and more, directly from H&E images. Lunit technology optimizes clinical trial processes, powering PD-L1 scoring for Guardant Health's Galaxy PD-L1 tissue testing. Lunit collaborates globally to advance oncology therapeutic biomarkers, driven by the company’s commitment to innovation and excellence.